](/_ipx/q_100,fit_outside,s_360x255/images/no-image-product-box.jpg "SARS-CoV-2 Spike P681H Antibody [7A4D12](Alpha, Mu Variant)")
](/_ipx/_/images/no-image-product-box.jpg "SARS-CoV-2 Spike P681H Antibody [7A4D12](Alpha, Mu Variant)")
SARS-CoV-2 Spike P681H Antibody [7A4D12](Alpha, Mu Variant)
1021.39 €
In Stock
quantity
product details
Catalog number: 223 - PM-9374-01mg
Product Category: Business & Industrial > Science & Laboratory
Gentaur
Size: 0.1 mg
9359-002mg
SARS-CoV-2 Spike P681H Antibody (Alpha, Mu Variant)
In September of 2020 a new lineage of SARS-CoV-2, known as B.1.1.7, was discovered in the United Kingdom. This lineage was found to have developed 14 lineage-specific amino acid replacements and 3 deletions prior to its discovery. The transmission of UK variant (B.1.1.7 lineage) was increased at least 50%. Increased severity and higher death rate were also found in UK variant. UK variant will not affect the effectiveness of COVID19 vaccine. One of the mutations associated with this lineage is a <strong>N501Y</strong> in the spike protein of the virus. It is believed that this mutation is able to increase the spike protein's affinity for the host ACE2 receptor and it has been associated with increased infectivity and virulence. B.1.1.7 viruses have also been shown to have a <strong>P681H</strong> in the cleavage site of spike protein. This location is one of the residues that make up the furin cleavage site between S1 and S2 in spike protein.
474.55 €
9359-01mg
SARS-CoV-2 Spike P681H Antibody (Alpha, Mu Variant)
In September of 2020 a new lineage of SARS-CoV-2, known as B.1.1.7, was discovered in the United Kingdom. This lineage was found to have developed 14 lineage-specific amino acid replacements and 3 deletions prior to its discovery. The transmission of UK variant (B.1.1.7 lineage) was increased at least 50%. Increased severity and higher death rate were also found in UK variant. UK variant will not affect the effectiveness of COVID19 vaccine. One of the mutations associated with this lineage is a <strong>N501Y</strong> in the spike protein of the virus. It is believed that this mutation is able to increase the spike protein's affinity for the host ACE2 receptor and it has been associated with increased infectivity and virulence. B.1.1.7 viruses have also been shown to have a <strong>P681H</strong> in the cleavage site of spike protein. This location is one of the residues that make up the furin cleavage site between S1 and S2 in spike protein.
1021.39 €
PM-9371-002mg
SARS-CoV-2 Spike P681H Antibody [9F7E4] (Alpha, Mu Variant)
In September of 2020 a new lineage of SARS-CoV-2, known as B.1.1.7 and named as Alpha variant, was discovered in the United Kingdom. This lineage was found to have developed 14 lineage-specific amino acid replacements and 3 deletions prior to its discovery. The transmission of alpha variant (B.1.1.7 lineage) was increased at least 50%. Increased severity and higher death rate were also found in apha variant. Alpha variant will not affect the effectiveness of COVID19 vaccine. One of the mutations associated with this lineage is a <strong>N501Y</strong> in the spike protein of the virus. It is believed that this mutation is able to increase the spike protein's affinity for the host ACE2 receptor and it has been associated with increased infectivity and virulence. B.1.1.7 viruses have also been shown to have a <strong>P681H</strong> mutation in the cleavage site of spike protein. This location is one of the residues that make up the furin cleavage site between S1 and S2 in spike protein.
474.55 €